PPARĪ³ Agonists | Characteristics |
---|---|
Balaglitazone | Phase III (Henriksen et al., 2011) |
Rivoglitazone | Phase III (see text) |
Metaglidasen (MBX 102; JNJ39659100) | Next generation: partial agonist lack of weight gain as side effect; anti-inflammatory actions (Gregoire et al., 2009) (phase III) |
MBX-2044 | Following MBX-102, is in phase II |
Netoglitazone (MCC-555, RWJ-241947) | No data |
R483 | Oxazole derivative, investigated in detail, e.g. with respect to CYP2C19 polymorphism (Bogman et al., 2010) |
MK-0533 | Selective and lower potential of increasing plasma and extracellular fluid volume (Acton et al., 2009) |
GSK 376501 | 1,3-Disubstituted indole 2-carboxylic acid, phase I |
GW-1929, farglitazar (GI-262570), GW-409544, JTT-501 and YM-440. | Nonthiazolidinediones |
MK-0533, (2R)-2-(3-{3-[(4-methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid; GW-1929, N-(2-benzoylphenyl)-O-[2-(methyl-2-pyridinylamino)ethyl]-l-tyrosine hydrochloride; GW-409544, (2S)-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]-2-[(4-oxo-4-phenylbutan-2-yl)amino]propanoic acid; JTT-501, 4-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzyl]-3,5-isoxazolidinedione; YM-440, (Z)-1,4-bis(4-((3,5-dioxo-1,2,4-oxadiazolidin-2-yl)methyl)phenoxy) but-2-ene; GSK 376501, 1,3-disubstituted indole 2-carboxylic acid.